The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
- 1 July 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (1), 380-383
- https://doi.org/10.1182/blood-2006-12-065599
Abstract
Because the polycomb group gene BMI1 regulates the proliferation of both normal and leukemic stem cells, we examined whether BMI1 expression was associated with disease progression in chronic myeloid leukemia (CML). Levels of BMI1 RNA were significantly higher in patients with advanced-phase than in patients with chronic-phase CML in both CD34+ cells (P = .006) and total peripheral-blood mononuclear cells (P < .001). E2F1, a transcription factor regulating BMI1, was up-regulated in CML compared with controls (P = .001). In a cohort of 64 CML patients, the level of BMI1 at diagnosis correlated with time to transformation to blast crisis, and the combination of low BMI1 and high proteinase-3 expression was associated in multivariate analysis with an improved overall survival (P = .001). We conclude that BMI1 may be a biomarker for the intrinsic heterogeneity of CML, and its measurement at diagnosis can help predict overall survival and thus contribute to better therapeutic decisions.Keywords
This publication has 23 references indexed in Scilit:
- Gene expression changes associated with progression and response in chronic myeloid leukemiaProceedings of the National Academy of Sciences, 2006
- Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosisBlood, 2006
- Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CMLBlood, 2006
- Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene SilencingMolecular Cell, 2005
- In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLBlood, 2005
- The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteinsCancer Letters, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Bmi-1 determines the proliferative capacity of normal and leukaemic stem cellsNature, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expressionBritish Journal of Cancer, 2001